- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Ajanta Pharma's board approved the financial results for the quarter and nine months. Consolidated revenue jumped 20% to ₹1,375 Cr, with profit after tax surging 18% to ₹274 Cr in Q3 FY26, driven by strong US Generics and India growth.